期刊文献+

新藤黄酸纳米脂质载体制备及其药剂学性质研究 被引量:7

Preparation of gambogenic acid loaded nanostructured lipid carriers and its pharmaceutical properties
原文传递
导出
摘要 目的制备新藤黄酸纳米结构脂质载体并表征其药剂学性质。方法采用乳化蒸发-低温固化法制备新藤黄酸纳米脂质载体(GNA-NLC),正交试验设计优化最佳工艺处方,并对其包封率、平均粒径及Zeta电位等性质进行考察。结果优化后处方制备的GNA-NLC多为圆整、实体的类球形,平均粒径为(144.07±1.44)nm,多分散系数为0.24±0.01,Zeta电位为(28.03±0.29)mV,包封率为(84.65±0.98)%,载药量为(4.21±0.05)%;DSC显示GNA纳米粒确已形成,并且GNA以非晶态分布在基质中。结论乳化蒸发-低温固化法能成功制备GNA-NLC,工艺简单,易于控制。 Objective To prepare and characterize gambogenic acid loaded nanostuctured lipid carrier (GNA-NLC). Methods GNA-NLC was prepared by emulsion evaporation-low temperature solidification method, and its optimal prescription was selected by orthogonal test design. The characteristics, such as encapsulation efficiency (EE), average diameter, and Zeta potential, were studied. Results GNA-NLC had a spherical shape with smooth surface with the average diameter of (144.07 ± 1.44) nm, polydispersity index (PI) of 0.24± 0.01, Zeta potential of (-28.03± 0.29)mV. The EE and drug loading were (84.65v 0.98)% and (4.21± 0.05)%, respectively. DSC indicated that GNA was dispersed as non-crystalline in matrix. Conclusion Emulsion evaporation-low temperature solidification method is easy, simple, and feasible to prepare GNA-NLC.
出处 《中草药》 CAS CSCD 北大核心 2013年第11期1400-1406,共7页 Chinese Traditional and Herbal Drugs
基金 国家"重大新药创制"科技重大专项(2009ZX09103-399) 安徽省高校省级自然科学研究重点项目(KJ2011A190)
关键词 新藤黄酸 纳米脂质载体 微柱离心法 乳化蒸发-低温固化法 正交试验设计 gambogenic acid nanosturured lipid carders mini-column centrifugation method emulsion evaporation-lowtemperature solidification method orthogonal test design
  • 相关文献

参考文献19

  • 1王鸣,冯煦,赵友谊,傅晖.中药藤黄的研究和应用[J].中国野生植物资源,2003,22(1):1-4. 被引量:40
  • 2Lee S B. Fractionated products obtained from gamboge resin and medical uses of the same: United States, US 20110305784 A1 [P]. 2011-12-15.
  • 3Yan F G, Wang M, Chen H, et al. Gambogenic acid mediated apoptosis through the mitochondrial oxidative stress and inactivation of Akt signaling pathway in human nasopharyngeal carcinoma CNE-1 cells [J]. Eur J Pharmacol, 2011, 652(1/3): 23-32.
  • 4Yan F G, Wang M, Li J M, et al. Gambogenic acid induced mitochondrial-dependent apoptosis and referred to Phospho-Erkl/2 and Phospho-p38 MAPK in human hepatoma HepG2 cells [J]. Environ Toxicol Pharmacol, 2012, 33(2): 181-190.
  • 5Cheng H, Su J J, Peng J Y, et al. Gambogenic acid inhibits proliferation of A549 cells through apoptosis inducing through up-regulation of the p38 MAPK cascade [J]. JAsian Nat Prod Res, 2011, 13(11): 993-1002.
  • 6Li Q L, Cheng H, Zhu G Q, et al. Gambogenic acid inhibits proliferation of A549 cells through apoptosis- inducing and cell cycle arresting [J]. Biol Pharm Bull, 2010, 33(3): 415-420.
  • 7胡海霞,王效山,彭代银,李庆林.新藤黄酸包合物冻干粉针制备及工艺优化[J].中草药,2012,43(1):65-69. 被引量:7
  • 8Muler R H, Shegokar R, Keck C M. 20 Years of lipid nanoparticles (SLN & NLC): Present state of development & industrial applications [J]. Curr Drug Discov Technol, 2011, 8(3): 207-227.
  • 9Attama A A. SLN, NLC, LDC: State of the art in drug and active delivery [J]. Recent Pat Drug Deliv Formul, 2011, 5(3): 178-187.
  • 10蒲宝婵,赵骏,邱超,张雪.复乳法制备龙胆苦苷脂质体[J].药物评价研究,2011,34(6):428-431. 被引量:3

二级参考文献50

共引文献56

同被引文献102

引证文献7

二级引证文献42

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部